Childhood acute lymphoblastic leukemia: current perspectives
- PMID: 11421142
Childhood acute lymphoblastic leukemia: current perspectives
Erratum in
- Oncol Nurs Forum 2001 Aug;28(7):1083
Abstract
Purpose/objectives: To provide an overview of childhood acute lymphoblastic leukemia (ALL), including epidemiology, clinical presentation, diagnostic classification, prognostic factors, current treatment, long-term sequelae, and nursing management.
Data sources: Journal articles, books, and clinical experience.
Data synthesis: Childhood ALL is a heterogeneous disorder, and current treatment is tailored to risk factors (e.g., initial white blood count, cytogenetic properties of the leukemic blasts). Risk-directed therapy ensures that children with a higher risk of relapse receive more intensive treatment, whereas those with lower risk disease receive less toxic therapy with decreased potential for treatment-related morbidity. Quality of life in long-term survivors is a significant issue. Late sequelae of treatment can include neurocognitive difficulties, endocrine dysfunction, secondary malignancies, and cardiomyopathy.
Conclusions: With risk-directed therapy, cure rates for childhood ALL continue to improve. At least 80% of children diagnosed with ALL today are expected to survive their disease.
Implications for nursing practice: Nurses caring for children with ALL can have a significant impact on the children's overall health, from diagnosis through long-term follow-up. Nursing interventions encompass the domains of physical and psychosocial care, as well as patient and family education. Assisting the child and family to maintain normalcy in the face of chronic illness, as well as fostering the family's hope for the future and their belief in the child's potential for survival, are key nursing strategies that promote the child's growth, development, and psychological health.
Similar articles
-
Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.Pediatr Blood Cancer. 2005 Aug;45(2):111-20. doi: 10.1002/pbc.20363. Pediatr Blood Cancer. 2005. PMID: 15782402
-
Long-term outcomes in survivors of childhood acute lymphoblastic leukemia.Hematol Oncol Clin North Am. 2009 Oct;23(5):1065-82, vi-vii. doi: 10.1016/j.hoc.2009.07.003. Hematol Oncol Clin North Am. 2009. PMID: 19825453 Review.
-
Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia.Pediatr Blood Cancer. 2009 Aug;53(2):156-61. doi: 10.1002/pbc.21992. Pediatr Blood Cancer. 2009. PMID: 19405135
-
Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.Haematologica. 2008 Aug;93(8):1155-60. doi: 10.3324/haematol.12365. Epub 2008 Jun 2. Haematologica. 2008. PMID: 18519521
-
The childhood leukemias.J Pediatr Nurs. 2003 Apr;18(2):87-95. doi: 10.1053/jpdn.2003.9. J Pediatr Nurs. 2003. PMID: 12720205 Review.